SC

Satish Chand

Active Director Director DIN 02926684
DIN 02926684 First appointment Mar 2010 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2010
Shareholding value •••• Premium profile

About Satish Chand

Data last updated:

Satish Chand is a Director at Avert Pharma Private Limited (since 2010). The company operates in Pharma. Avert Pharma Private Limited reported revenue of ₹54.6 Lakh (FY 2024).

DIN 02926684
Primary Designation Director
Industry Pharma
First Appointment 10 Mar 2010
Oldest Company Age 16 yrs
Largest company Avert Pharma Private Limited · ₹54.6 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Avert Pharma Private Limited U36101DL2010PTC199918
Director10 Mar 20102010₹54.6 Lakh (FY 2024)Active

Board colleagues of Satish Chand

NameDINCompanyDesignation
Satendra Singh02926852Avert Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Avert Pharma Private Limited
Premium access

Shareholding and investment profile for Satish Chand

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Satish Chand

Satish Chand currently holds 1 directorship: Avert Pharma Private Limited (Director, since 10 Mar 2010, revenue ₹54.6 Lakh (FY 2024)).

Satish Chand was first appointed on 10 Mar 2010 as Director at Avert Pharma Private Limited.

The current boards of Satish Chand's companies include Satendra Singh (Avert Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available